

ΣΥΝΤΟΜΟ ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ

Επώνυμο Κωσταρά
Όνομα Χριστίνα
Διεύθυνση Εργασίας Επιστημονικός Συνεργάτης, Εργαστήριο Κλινικής Χημείας, Τμήμα Ιατρικής, Σχολή Επιστημών Υγείας, Πανεπιστήμιο Ιωαννίνων, 45110, Ιωάννινα
Τηλ: 2651007833, Fax: 2651007871
E-mail: chkostara@uoi.gr, chkostara@gmail.com

Τίτλοι σπουδών

Σε εξέλιξη Επί πτυχίω φοιτήτρια Τμήματος Ιατρικής, Σχολή Επιστημών Υγείας, Πανεπιστήμιο Ιωαννίνων

Απρίλιος 2018 Μεταπτυχιακό Δίπλωμα Ειδίκευσης, ΔΠΜΣ Ιατρική Χημεία, Τμήμα Χημείας, Σχολή Θετικών Επιστημών, Πανεπιστήμιο Ιωαννίνων.

Δεκέμβριος 2007 Διδακτορικό Δίπλωμα στο Γνωστικό Αντικείμενο της Κλινικής Χημείας, Εργαστήριο Κλινικής Χημείας, Τμήμα Ιατρικής, Σχολή Επιστημών Υγείας, Πανεπιστήμιο Ιωαννίνων.

Ιούλιος 2003 Πτυχίο Χημείας, Τμήμα Χημείας, Σχολή Θετικών Επιστημών, Πανεπιστήμιο Ιωαννίνων.

Ερευνητικά Ενδιαφέροντα

Διερεύνηση των μηχανισμών παθολογικών καταστάσεων μέσω της συνολικής ανάλυσης του λιπιδικού προφίλ (Lipidomics) των βιολογικών συστημάτων (βιολογικά υγρά, ιστοί και κύτταρα) στα πλαίσια του γενικότερου ερευνητικού πεδίου της Μεταβολομικής (Metabonomics) με Φασματοσκοπία Πυρηνικού Μαγνητικού Συντονισμού (Nuclear Magnetic Resonance spectroscopy).

Επιστημονικές Εργασίες

32	Δημοσιεύσεις σε Διεθνή Περιοδικά μετά από Κρίση
1	Κεφάλαιο σε Ξερόγλωσσο Βιβλίο
142	Ανακοινώσεις σε Διεθνή και Ελληνικά Συνέδρια

Αναφορές: 1018, **h-index:** 18 (Google Scholar, 12/2022)

Δημοσιεύσεις σε Διεθνή Περιοδικά

1. Spanou L, Dimou A, **Kostara CE**, Bairaktari E, Anastasiou E, Tsimihodimos V. A Study of the Metabolic Pathways Affected by Gestational Diabetes Mellitus: Comparison with Type 2 Diabetes. *Diagnostics (Basel)*. 2022;12(11):2881.
2. Kordias D, **Kostara CE**, Papadaki S, Verigos J, Bairaktari E, Magklara A. Omics Analysis of Chemoresistant Triple Negative Breast Cancer Cells Reveals Novel Metabolic Vulnerabilities. *Cells*. 2022; 11(17): 2719.
3. Pappa E, **Kostara C**, Bairaktari E, Arvaniti E, Tsimihodimos V. Effect of fixed-dose combination of insulin degludec and liraglutide on apoB-containing lipoprotein subclasses and HDL lipidome in type 2 diabetes. *J Diabetes Complications*. 2022; 36(10): 108286.
4. **Kostara CE**, Karakitsou KS, Florentin M, Bairaktari ET, Tsimihodimos V. Progressive, Qualitative, and Quantitative Alterations in HDL Lipidome from Healthy Subjects to Patients with Prediabetes and Type 2 Diabetes. *Metabolites*. 2022; 12(8): 683.
5. Kosmas CE, Sourlas A, Guzman E, **Kostara CE**. Environmental Factors Modifying HDL Functionality. *Curr Med Chem*. 2022; 29(10): 1687-1701.
6. **Kostara CE**, Tsiafoulis CG, Bairaktari ET, Tsimihodimos V. Altered RBC membrane lipidome: A possible etiopathogenic link for the microvascular impairment in Type 2 diabetes. *J Diabetes Complications*. 2021; 35(10): 107998.
7. Kuusisto S, **Kostara C**, Kangas AJ, Perola M, Salomaa V, Kettunen J, Ala-Korpela M. HDL-Mediated Cholesterol Efflux Associates with Incident Kidney Disease. *Clin Chem*. 2021; 67(4): 689-691.
8. Bletsas E, Filippas-Dekouan S, **Kostara C**, Dafopoulos P, Dimou A, Pappa E, Chasapi S, Spyroulias G, Koutsovasilis A, Bairaktari E, Ferrannini E, Tsimihodimos V. Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes. *J Clin Endocrinol Metab*. 2021; 106(5): 1269-1283.
9. **CE Kostara**, E Ferrannini, ET Bairaktari, A Papathanasiou, M Elisaf, V Tsimihodimos. Early signs of atherogenic features in the HDL lipidome of normolipidemic patients, newly diagnosed with type 2 diabetes. *Int J Mol Sci*. 2020; 21(22): 8835.
10. S Kartsoli, **CE Kostara**, V Tsimihodimos, ET Bairaktari, DK Christodoulou. Lipidomics in non-alcoholic fatty liver disease. *World J Hepatol* 2020; 12: 436-450.
11. Pappa E, Elisaf M, **Kostara C**, Bairaktari E, Tsimihodimos V. Cardioprotective Properties of Hdl: Structural And Functional Considerations. *Curr Med Chem*. 2020; 27: 2964-2978.
12. **Kostara CE**, Lekkas P, Vezyraki P, Angelidis C, Deligiannis IK, Bairaktari ET, Kalfakakou V. Lipidome of plasma lipoproteins and liver is zinc- modulated in High fat diet treated mice. *J Trace Elem Med Biol*. 2018; 50: 268-275.
13. Tzavella E, Hatzimichael E, **Kostara C**, Bairaktari E, Elisaf M, Tsimihodimos V. Sitosterolemia: A multifaceted metabolic disorder with important clinical consequences. *J Clin Lipidol*. 2017; 11: 1095-1100.
14. **Kostara CE**, Tsimihodimos V, Elisaf MS, Bairaktari ET. NMR-Based Lipid Profiling of High Density Lipoprotein Particles in Healthy Subjects with Low, Normal, and Elevated HDL-Cholesterol. *J Proteome Res*. 2017; 16: 1605-1616.

15. Liberopoulos EN, Apostolou F, Gazi IF, **Kostara C**, Bairaktari ET, Tselepis AD, Elisaf M. Visceral leishmaniasis is associated with marked changes in serum lipid profile. *Eur J Clin Invest*. 2014; 44:719-727.
16. **Kostara CE**, Papathanasiou A, Psychogios N, Cung MT, Elisaf MS, Goudevenos J, Bairaktari ET. NMR-based lipidomic analysis of blood lipoproteins differentiates the progression of coronary heart disease. *J Proteome Res*. 2014; 13: 2585-2598.
17. Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, **Kostara C**, Gartzonika C, Bairaktari ET, Millionis HJ. Effects of Rosuvastatin With or Without Ezetimibe on Clinical Outcomes in Patients Undergoing Elective Vascular Surgery: Results of a Pilot Study. *J Cardiovasc Pharmacol Ther* 2013; 18: 5-12.
18. Agouridis AP, Kostapanos MS, Tsimihodimos V, **Kostara C**, Mikhailidis DP, Bairaktari ET, Tselepis AD, Elisaf MS. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω -3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. *Int J Clin Pract* 2012; 66: 843-853.
19. Tzouvaras V, Tsimihodimos V, **Kostara C**, Mitrogianni Z, Elisaf M. Aminoglycoside-induced nephrotoxicity studied by proton magnetic resonance spectroscopy of urine. *Nephrol Dial Transplant* 2011; 26: 3219-3224.
20. Nakou ES, Filippatos TD, Agouridis AP, **Kostara C**, Bairaktari ET, Elisaf MS. The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. *Lipids* 2010; 45: 445-50.
21. Rizos CV, Millionis HJ, Kostapanos MS, Florentin M, **Kostara CE**, Elisaf MS, Liberopoulos EN. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week randomized, open-label, prospective study. *Clin Ther* 2010; 32: 492-505.
22. **Kostara CE**, Papathanasiou A, Cung MT, Elisaf MS, Goudevenos J, Bairaktari ET. Evaluation of Established Coronary Heart Disease on the Basis of HDL and Non-HDL NMR Lipid Profiling. *J Proteome Res* 2010; 9: 897-911.
23. Tsimihodimos V, Gazi I, Filippatos T, Kostapanos M, Lagos K, **Kostara C**, Tellis CC, Elisaf M, Tselepis AD. Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia. *Atherosclerosis* 2010; 208: 506-511.
24. Tzouvaras VT, Psychogios NG, **Kostara CE**, Bairaktari ET, Elisaf MS. Evaluation of the proximal tubular function in individuals with primary renal hypouricemia: an NMR-based metabolomic study. *NMR Biomed* 2009; 22: 1072-1083.
25. Florentin M, Liberopoulos E, Filippatos T, **Kostara C**, Tselepis A, Mikhailidis D, Elisaf M. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. *Expert Opin Pharmacother* 2008; 9: 2741-2750.
26. TD Filippatos, V Tsimihodimos, M Kostapanos, **C Kostara**, ET Bairaktari, DN Kiortis, AD Tselepis, MS Elisaf. Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome. *Arch Med Sci* 2008; 4: 263-269.

27. TD Filippatos, V Tsimihodimos, M Kostapanos, **C Kostara**, ET Bairaktari, DN Kiortsis, MS Elisaf. Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. *J Clin Lipidol* 2008; 2: 279-284.
28. Papathanasiou A, **Kostara C**, Cung MT, Seferiadis K, Elisaf M, Bairaktari E, Goudevenos IA. Analysis of the composition of plasma lipoproteins in Patients with Extensive Coronary Heart Disease by ¹H NMR Spectroscopy. *Hellenic J Cardiol* 2008; 49: 72-78.
29. Kostapanos MS, Milionis HJ, Saougos VG, Lagos KG, **Kostara C**, Bairaktari ET, Elisaf MS. Dose-Dependent Effect of Rosuvastatin Treatment on Urinary Protein Excretion. *J Cardiovasc Pharmacol Ther* 2007; 12: 292-297
30. Tsimihodimos V, Gazi I, **Kostara C**, Tselepis AD, Elisaf M. Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles. *Lipids* 2007; 42: 403-409.
31. MS Kostapanos, HJ Milionis, I Gazi, **C Kostara**, ET Bairaktari, M Elisaf. Rosuvastatin increases α -1 microglobulin urinary excretion in patients with primary dyslipidemia. *J Clin Pharmacol* 2006; 46: 1337-1343.
32. AG Georgiadis, EC Papavasiliou, ES Lourida, Y Alamanos, **C Kostara**, AD Tselepis, AA Drosos. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. *Arthritis Res Ther* 2006; 8: R82-88.

Κεφάλαιο σε Βιβλίο

1.	Kostara CE , Bairaktari ET. "Lipid profiling in health and disease" in "Methodologies for Metabolomics: Experimental Strategies and Techniques". Lutz N, Sweedler J and Wevers RA, Eds., Cambridge University Press, 2012, p.317-332 . ISBN: 9780521765909
-----------	---